SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2012 / Cilt: 12 - Sayı: 3

Güçlendirilmiş dışardan kontrpulsasyon tedavisinin iskemik kalp yetersizliği olan hastalarda klinik etkileri

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Dilek URAL
Fatih AYGÜN
Gökhan ERTAŞ
Özden SORAN
Ender EMRE
Ahu KIRBAŞ
Güliz KOZDAĞ
Pages
214–221
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: EECP therapy resulted in significant improvement in post-intervention New York Heart Association functional class (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Enhanced external counterpulsation (EECP) is a noninvasive treatment that is proven safe and effective in patients with coronary artery disease (CAD) and heart failure (HF).
📊
Key Findings & Data:A total of 68 consecutive patients with symptomatic CAD and chronic HF referred to EECP therapy were enrolled in this study between November 2007 and December 2010; 47 patients (39 males and 8 females, 65±7, years), have undergone EECP treatment, and 21 patients (20 males and 1 female, 62±10 years), who did not want to participate in the EECP program comprised the control group.
💡
Conclusion & Impact:Results: EECP therapy resulted in significant improvement in post-intervention New York Heart Association functional class (p
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Enhanced external counterpulsation (EECP) is a noninvasive treatment that is proven safe and effective in patients with coronary artery disease (CAD) and heart failure (HF). The aims of this study are to investigate the clinical effects of EECP therapy in patients with symptomatic CAD and chronic HF, and to find out an answer to the question: Does EECP therapy have any effect on the prognostic markers of HF? Methods: This study was designed as a prospective cohort study. A total of 68 consecutive patients with symptomatic CAD and chronic HF referred to EECP therapy were enrolled in this study between November 2007 and December 2010; 47 patients (39 males and 8 females, 65±7, years), have undergone EECP treatment, and 21 patients (20 males and 1 female, 62±10 years), who did not want to participate in the EECP program comprised the control group. Statistical analysis was performed using t tests for dependent and independent samples, Mann-Whitney U test, Chi-square and Fischer exact tests. Results: EECP therapy resulted in significant improvement in post-intervention New York Heart Association functional class (p

Özet

Amaç: Güçlendirilmiş dışardan kontrpulsasyon (EECP), koroner arter hastalığı (KAH) ve kalp yetersizliği (KY) olan hastalarda güvenli ve efektif olduğu kanıtlanmış invaziv olmayan bir tedavi yöntemidir. Bu çalışmanın amacı EECP tedavisinin semptomatik KAH ve KY olan hastalardaki klinik etkilerini araştırmak ve EECP tedavisinin KYnin prognostik faktörleri üzerine herhangi bir etkisi var mı? Sorusuna cevap bulmak. Yöntemler: Bu çalışma prospektif kohort çalışma olarak dizayn edildi. Kasım 2007 ve Aralık 2010 arasında EECP tedavisi için başvuran 68 semptomatik KAH ve kronik KY olan hasta çalışmaya dahil edildi. 47 hasta (39 erkek ve 8 kadın, 65±7, yaş) EECP tedavisine alındı. EECP programına katılmak istemeyen 21 hasta (20 erkek ve 1 kadın, 62±10 yaş) kontrol grubunu oluşturdu. Sürekli değişkenler 2-tailed t test ve Mann-Whitney U testi ile analiz edildi. Kategorik veriler ve oranlar χ2 veya Fisher exact test ile analiz edildi. Bulgular: EECP tedavisi sonrası New York Kalp Cemiyeti'nin fonksiyonel sınıflaması (p

🔖

Cite This Article

URAL, D., AYGÜN, F., ERTAŞ, G., SORAN, Ö., EMRE, E., KIRBAŞ, A., KOZDAĞ, G. (2022). Güçlendirilmiş dışardan kontrpulsasyon tedavisinin iskemik kalp yetersizliği olan hastalarda klinik etkileri. Anadolu Kardiyoloji Dergisi, Cilt: 12 - Sayı: 3, 214–221. https://ajindex.com/articles/436480

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Serruys PW, Aoki J. Therapeutic options for patients with chronic myocardial ischemia. Eur Heart J Suppl 2004; 6: 12-7
  2. Manchanda A, Soran O. Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure. J Am Coll Cardiol 2007; 50: 1523-31
  3. Pettersson T, Bondesson S, Cojocaru D, Ohlsson O, Wackenfors A, Edvinsson L. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Disord 2006; 6: 28
  4. Bonetti PO, Holmes DR Jr, Lerman A, Barsness GW. Enhanced external counterpulsation for ischemic heart disease: what’s behind the curtain? J Am Coll Cardiol 2003; 41: 1918-25
  5. Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 2002; 23: 355-70
  6. Holmes DR Jr. Treatment options for angina pectoris and the future role of enhanced external counterpulsation. Clin Cardiol 2002; 25(12 Suppl 2): II22-5
  7. Soran O. Efficacy and safety of enhanced external counterpulsation in mild to moderate heart failure: a preliminary report (abstr). J Card Fail 1999; 3 Suppl 1: 195
  8. Soran O, Fleishman B, Demarco T, Grossman V, Schneider VM, Manzo K, et al. Enhanced external counterpulsation in patients with heart failure: a multicenter feasibility study. Congest Heart Fail 2002; 8: 204-8
  9. Arora RR, Shah AG. The role of enhanced external counterpulsation in the treatment of angina and heart failure. Can J Cardiol 2007; 23: 779-81. 10 Scardovi AB, De Maria R, Celestini A, Coletta C, Aspromonte N, Perna S, et al. Prognostic value of brain natriuretic peptide and enhanced ventilatory response to exercise in patients with chronic heart failure. Intern Emerg Med 2008; 3: 331-7
  10. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112: 1121-7
  11. Kozdağ G, Ertaş G, Kılıc T, Acar E, Ağır A, Şahin T, et al. Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. Med Sci Monit 2010; 16: CR156-61
  12. Manzano L, Babalis D, Roughton M, Shibata M, Anker SD, Ghio S, et al. SENIORS Investigators. Predictors of clinical outcomes in elderly patien